The study combines InnoCare's SHP2 allosteric inhibitor, ICP-189, with ArriVent's furmonertinib, an EGFR inhibitor, for patients with advanced or metastatic NSCLC.

Context Therapeutics Inc. (Nasdaq: CNTX) has submitted an Investigational New Drug (IND) application to the U.S. FDA for CTIM-76.

Surrozen has reported positive preliminary results from its Phase 1a clinical trial of SZN-043, a drug designed to treat severe alcohol-associated hepatitis.

Equillium, Inc., a clinical-stage biotech firm, has reported positive primary results from the Phase 1b EQUALISE study's Type B segment, which assessed the efficacy of itolizumab in lupus nephritis patients.

The pharmaceutical industry is experiencing a surge in the sales of injectable GLP-1 drugs for weight loss, with Eli Lilly's Zepbound recently surpassing Novo Nordisk's Wegovy in new U.S. prescriptions.

The trial will assess the efficacy of BioInvent's monoclonal antibody, BI-1910, when used in conjunction with Merck's KEYTRUDA® (pembrolizumab)

FG-3246 has shown promising results in treating adenocarcinoma within a heavily pre-treated patient group.

Kiromic BioPharma, Inc. has announced early indications of tumor stabilization in a patient enrolled in the Deltacel-01 Phase 1 clinical trial.

NANOBIOTIX has completed the dose escalation phase of a Phase 1 study evaluating NBTXR3, a potential first-in-class radioenhancer.

Corbus Pharmaceuticals, a precision oncology firm, has initiated a Phase 1 clinical trial in the U.S. for CRB-701 (SYS6002)

A clinical trial for a gene-editing treatment by Verve Therapeutics, known as VERVE-101, has been halted after a participant experienced severe side effects.

In a significant medical advancement, Ractigen Therapeutics has initiated its first-ever human clinical trial for RAG-01, a novel small activating RNA (saRNA) treatment for NMIBC.